Stock Track | Travere Therapeutics Soars 11.3% After-Hours on Strong FILSPARI Sales Growth and Q2 Product Revenue Beat

Stock Track

Aug 05

Travere Therapeutics, Inc. (TVTX) stock surged 11.3% in after-hours trading following the release of the company's second-quarter financial results, which highlighted robust demand for its kidney disease drug, FILSPARI.

Total net product sales for the quarter reached $161.352 million, representing a 70% increase year-over-year. The standout performer was FILSPARI, with U.S. net product sales climbing 96% year-over-year. This growth was fueled by the continued expansion in IgA nephropathy (IgAN) and the early launch of the drug for focal segmental glomerulosclerosis (FSGS).

The company reported a net loss of $34.8 million, or $0.37 per share, which included a $40 million inducement expense related to convertible note repurchases. Despite the net loss, the significant sales beat and the strong commercial trajectory for FILSPARI appear to be the primary catalysts driving the positive investor sentiment in the extended session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1115411697"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115411697\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115411697?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 04:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115411697","market":"nz","top_or_hot":-1,"title":"Stock Track | Travere Therapeutics Soars 11.3% After-Hours on Strong FILSPARI Sales Growth and Q2 Product Revenue Beat","media":"Stock Track","content":"<p>Travere Therapeutics, Inc. (TVTX) stock surged 11.3% in after-hours trading following the release of the company's second-quarter financial results, which highlighted robust demand for its kidney disease drug, FILSPARI.</p><p>Total net product sales for the quarter reached $161.352 million, representing a 70% increase year-over-year. The standout performer was FILSPARI, with U.S. net product sales climbing 96% year-over-year. This growth was fueled by the continued expansion in IgA nephropathy (IgAN) and the early launch of the drug for focal segmental glomerulosclerosis (FSGS).</p><p>The company reported a net loss of $34.8 million, or $0.37 per share, which included a $40 million inducement expense related to convertible note repurchases. Despite the net loss, the significant sales beat and the strong commercial trajectory for FILSPARI appear to be the primary catalysts driving the positive investor sentiment in the extended session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Travere Therapeutics Soars 11.3% After-Hours on Strong FILSPARI Sales Growth and Q2 Product Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Travere Therapeutics Soars 11.3% After-Hours on Strong FILSPARI Sales Growth and Q2 Product Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-05 04:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Travere Therapeutics, Inc. (TVTX) stock surged 11.3% in after-hours trading following the release of the company's second-quarter financial results, which highlighted robust demand for its kidney disease drug, FILSPARI.</p><p>Total net product sales for the quarter reached $161.352 million, representing a 70% increase year-over-year. The standout performer was FILSPARI, with U.S. net product sales climbing 96% year-over-year. This growth was fueled by the continued expansion in IgA nephropathy (IgAN) and the early launch of the drug for focal segmental glomerulosclerosis (FSGS).</p><p>The company reported a net loss of $34.8 million, or $0.37 per share, which included a $40 million inducement expense related to convertible note repurchases. Despite the net loss, the significant sales beat and the strong commercial trajectory for FILSPARI appear to be the primary catalysts driving the positive investor sentiment in the extended session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1115411697","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115411697","pubTimestamp":1785875733,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Travere Therapeutics, Inc. (TVTX) stock surged 11.3% in after-hours trading following the release of the company's second-quarter financial results, which highlighted robust demand for its kidney...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"股票跟踪 | 由于 FILSPARI 销售强劲增长和第二季度产品收入超出预期，Travere Therapeutics 盘后股价飙升 11.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Travere Therapeutics, Inc. (TVTX) stock surged 11.3% in after-hours trading following the release of the company's second-quarter financial results, which highlighted robust demand for its kidney disease drug, FILSPARI.Total net product sales for the quarter reached $161.352 million, representing a 70% increase year-over-year. The standout performer was FILSPARI, with U.S. net product sales climbing 96% year-over-year. This growth was fueled by the continued expansion in IgA nephropathy (IgAN) and the early launch of the drug for focal segmental glomerulosclerosis (FSGS).The company reported a net loss of $34.8 million, or $0.37 per share, which included a $40 million inducement expense related to convertible note repurchases. Despite the net loss, the significant sales beat and the strong commercial trajectory for FILSPARI appear to be the primary catalysts driving the positive investor sentiment in the extended session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}